louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01637350: Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes
Official title: The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastric Cancer
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
First posted: 2012-07-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: gastric cancer with type 2 diabetes,18\~75 years old,without serious underlying diseases

Brief summary: Different digestive tract reconstruction will affect the blood glucose level of gastric cancer with type 2 diabetes. Subtotal gastrectomy with Billroth II reconstruction and total gastrectomy with Roux-en-Y reconstruction may help to improve glycaemic control which includes fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of gastric cancer patients with type 2 diabetes.

Detailed description: Different digestive tract reconstruction will affect the blood glucose level of gastric cancer with type 2 diabetes. Subtotal gastrectomy with Billroth II reconstruction and total gastrectomy with Roux-en-Y reconstruction may help to improve glycaemic control which includes fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of gastric cancer patients with type 2 diabetes.

The investigators will observed fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of the patients preoperation, 14 days postoperation 3 month and 6month postoperation. The investigators will observed the effect of blood glucose to different digestive tract reconstruction after gastrectomy of gastric cancer with type 2 diabetes

Eligibility criteria: Inclusion Criteria:

1. 18-75 years old,gastric cancer ,can be performed operation
2. with type 2 diabetes,fasting blood glucose \> 6.1mmol/L
3. without serious underlying diseases which may affect the metabolism and nutrient uptake
4. without serious underlying diseases which may affect anesthesia and operation
5. can be performed subtotal or total gastrectomy, predicted survival period \> 6months
6. no other abdominal operation
7. preoperation consultation
8. informed consent

Exclusion Criteria:

1. recurrent,metastasis or die
2. patient requests for quit
3. pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital
state: Tianjin
Study officials:
affiliation: Tianjin Medical University Cancer Institute and Hospital
name: Zhao Yan, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01027650: Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Macular Edema
Retinal Vein Occlusion
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2009-12-08
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion. This study is being conducted in two stages: Stage 1 will enroll approximately 21 subjects who will receive a single open label intravitreal injection of either 75 ug, 300 ug, 600 ug or 900 ug of AGN208397 and be followed for 12 months post treatment; based on Stage 1 results, Stage 2 will enroll approximately 96 subjects who will receive a single masked intravitreal injection of one of three doses of AGN208397 or Ozurdex® and be followed for 12 months post treatment.


Eligibility criteria: Inclusion Criteria:

* macular edema due to retinal vein occlusion
* visual acuity in the study eye between 20/320 to 20/40

Exclusion Criteria:

* cataract surgery or Lasik within 3 months prior to study Day 1 or anticipated need for cataract surgery during study period (12 months)
* use of injectable drugs in the study eye within 2 months prior to day 1
* active eye infection in either eye
* visual acuity in the non-study eye of 20/200 or worse

Primary outcomes:
measure: Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 1
timeFrame: Baseline, Month 1
measure: Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 2
timeFrame: Baseline, Month 1
measure: Change From Baseline at Month 1 in Best Corrected Visual Acuity (BCVA) in the Study Eye During Stage 1
timeFrame: Baseline, Month 1
measure: Change From Baseline at Month 1 in BCVA in the Study Eye During Stage 2
timeFrame: Baseline, Month 1
Secondary outcomes:
measure: Change From Baseline at Month 12 in Retinal Thickness in the Study Eye During Stage 1
timeFrame: Baseline, Month 12
measure: Change From Baseline at Month 12 in Retinal Thickness in the Study Eye During Stage 2
timeFrame: Baseline, Month 12
measure: Change From Baseline at Month 12 in BCVA in the Study Eye During Stage 1
timeFrame: Baseline, Month 12
measure: Change From Baseline at Month 12 in BCVA in the Study Eye During Stage 2
timeFrame: Baseline, Month 12
Other outcomes:
Locations:
city: Phoenix
country: United States
state: Arizona
city: East Melbourne
country: Australia
state: Victoria
city: London
country: Canada
state: Ontario
city: Tel Aviv
country: Israel
city: Cape Town
country: South Africa
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02113150: A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery
Official title: A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Keywords: troponin t,cystatin-c,ketamine,remifentanil
Lead sponsor: Turkiye Yuksek Ihtisas Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2014-04-14
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: In this prospective, randomized, clinical trial, we have investigated the effects of ketamine-based and remifentanil-based anesthetic protocol on perioperative serum cystatin-c levels, and creatinine and/or cystatin-c based eGFR equations in terms of acute kidney injury in CABG surgery.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Patients scheduled for elective CABG with cardiopulmonary bypass. Patients were randomly allocated to anesthesia with remifentanil-propofol-midazolam (RPM) group or ketamine-propofol-midazolam (KPM) group. Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1, 2, and 4.


Eligibility criteria: Inclusion Criteria:

patients undergoing elective CABG with cardiopulmonary bypass

Exclusion Criteria:

patients undergoing emergency operation, combined operation, off-pump surgery, repeat surgery or valve surgery, patients presenting with chronic kidney disease or renal impairment, patients younger than 18 years old and neurological and/or psychiatric disturbances.

Primary outcomes:
measure: creatinin, BUN
timeFrame: 2 months
Secondary outcomes:
measure: Cystatin-c level
timeFrame: 2 months
Other outcomes:
measure: GFR value
timeFrame: 2 months
Locations:
city: Ankara
country: Turkey
facility: Aslı Demir
city: Ankara
country: Turkey
facility: Turkey Yuksek Ihtisas Education and Research Hospital
Study officials:
affiliation: Turkey Yuksek Ihtisas Education and Research Hospital
name: Aslı Demir
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03149250: Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia
Official title: Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia - a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coagulation Disorder, Blood
Platelet Function
Keywords: Aggregometry
Lead sponsor: Goethe University
Sponsor class: OTHER
First posted: 2017-05-11
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant patients suffering from preeclampsia, n = 20

Control group 1: Healthy pregnant patients, not suffering from preeclampsia, n=20

Control group 2: Healthy woman (age between 18 and 40y) that are not pregnant

Brief summary: The study aims to investigate the impact of preeclampsia on hemostasis.

Detailed description: In comparison to healthy pregnant women and non-pregnant woman, this study analyses parameters of primary hemostasis and plasmatic coaguation in preeclamptic pregnant woman. Detailed analyses of the platelet function is performed using the Multiple Electrode Aggregometry, detailed analyses of the plasmatic coagulation syste is performed by isolated coaguation factor analyses and conventional coagulation analyses.

Eligibility criteria: Inclusion Criteria:

* Platelet count \> 100 / nll
* In study group and control group 1: Week of Pregnancy: 35-40
* in control group 2: healthy, not pregnant woman

Exclusion Criteria:

* Hereditary coagulopathy
* Missing content of the patient / proband
* Eclampsia
* HELLP syndrome
* CRP \> 1 mg/dl
* Fever (\> 38°C)

Primary outcomes:
measure: Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry
timeFrame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
Secondary outcomes:
measure: Area under the aggregation curve in the ASPItest of the Multiple Electrode Aggregometry
timeFrame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
measure: Area under the aggregation curve in the TRAPtest of the Multiple Electrode Aggregometry
timeFrame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
measure: Parameters of plasmatic coagulation system
timeFrame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
Other outcomes:
Locations:
Study officials:
affiliation: Goethe University
name: Christian F Weber, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00625950: Endometriosis Patients Undergoing Quinagolide Treatment
Official title: Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hyperprolactinemia
Endometriosis
Keywords: Hyperprolactinemia
Endometriosis
laparoscopy
angiogenesis, VEGF
Lead sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor class: OTHER
First posted: 2008-02-29
Enrollment: 5
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.


Eligibility criteria: Inclusion Criteria:

* Hyperprolactinemia
* Unexplained infertility
* Endometriosis

Primary outcomes:
measure: observation of three month treatment with Quinagolida in endometriosis patients
timeFrame: onset and three months after onset
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Instituto Valenciano de Infertilidad
Study officials:
References:
citation: Gomez R, Abad A, Delgado F, Tamarit S, Simon C, Pellicer A. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril. 2011 Mar 1;95(3):882-8.e1. doi: 10.1016/j.fertnstert.2010.10.024. Epub 2010 Nov 5.
Clinical trial NCT02387450: Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
Official title: Reduction de la Morbi-mortalité Cardiovasculaire Chez l'artériopathe Claudicant Par le Sildenafil
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Peripheral Arterial Disease
Keywords: Claudication
Maximal walking distance
Morbi-mortality
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2015-03-13
Enrollment: 400
Sex: ALL
Minimum age (years): 30
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sildenafil has shown potential effects both on vasodilator mechanisms and as an inhibitor of the NO/GMPc Pain activation. The investigators aim at estimating the benefit of sildenafil in term of morbi-mortality in patients with arterial claudication on a multicenter prospective double blind study.

Detailed description: Eligible patients will ask to participate after oral and written information. Evaluation of walking capacity (self reported and treadmill measured), co-morbid condition and quality of life (WELCH, SF-36, Edinburg) will be performed at inclusion, after the first dose and at 3 months of oral treatment through sildenafil 100mg/day or placebo from inclusion to 3 months.

Indication for revascularisation will be evaluated at 3 months according to symptoms and walking capacity according to the Rutherford classification.

Primary endpoint is the proportion of patients showing either a fatal events (cardio-vascular or noncardiovascular) or hospitalisation for non fatal cardiovascular events at 6 and 9 months follow up from inclusion.

Eligibility criteria: Inclusion Criteria:

* ABI\<0.90
* Vascular type claudication
* stable walking impairment for at least 3 months
* Optimal cardiovasc treatment (Anti-platelet, HMGCoA-Inh, ACE-Inh or AT2 inh)
* Age \> 30 years

Exclusion Criteria:

* Refuse to participate
* Administrative protection
* Severe renal (clearance \< 30 ml/min) or hepatic (Child-Pugh C) failure

Primary outcomes:
measure: Morbi-mortality : combined criterion (Cardiovascular fatal and non fatal event Improvement of 1 stage)
timeFrame: 6 months
Secondary outcomes:
measure: Quality of life Questionnaire
timeFrame: 3, 6 and 9 months
measure: Safety and secondary effects (Headache, Hypotension) (Proportion of Participants with Adverse Event)
timeFrame: 3, 6 and 9 months
measure: Walking capacity (treadmill test)
timeFrame: 3, 6 and 9 months
measure: Proportion of revascularized patients
timeFrame: 6 and 9 months
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre hospitalier universitaire
Study officials:
affiliation: University Hospital in Angers
name: pierre Abraham, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04960150: EFFECTS OF ACUPUNCTURE ON LEG MUSCLE STRENGTH
Official title: EFFECTS OF ACUPUNCTURE ON LEG MUSCLE STRENGTH: RANDOMIZED CONTROLLED TRIAL IN SPORTS STUDENTS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Health, Subjective
Muscle Strength
Keywords: acupuncture
press tack needle
leg strength
Lead sponsor: Indonesia University
Sponsor class: OTHER
First posted: 2021-07-13
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Press tack needle is one of the acupuncture modalities in the form of needles that are attached to the skin, and can be left attached to the skin for several days which makes its use much easier than conventional acupuncture.

The purpose of this study was to determine how the effect of press tack needle acupuncture on leg muscle strength performed on sports students.

Research subjects as many as 30 people were randomized into two groups, namely the intervention group and the control group. In the intervention group, acupuncture treatment was performed with a press tack needle at acupuncture points on the legs. The leg muscle strength was measured using a leg dynamometer before and after the acupuncture intervention. Analyzed the difference in mean leg muscle strength before and after the intervention, and between the two groups.


Eligibility criteria: Inclusion Criteria:

* willingness to fill out an informed consent form;
* age between 18-25 years;
* male;
* has a BMI value of 18.5-22.9 kg/m2;
* there is no history of injury or history of surgery on the lower extremities in the last three months;
* the individual is in good health.

Exclusion Criteria:

* absence or refusal to be examined and not cooperative.

Primary outcomes:
measure: Leg muscle strength
timeFrame: baseline (Before intervention)
measure: Leg muscle strength
timeFrame: 35 minutes after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Jakarta
country: Indonesia
facility: Sport Science Faculty, Universitas Negeri Jakarta
Study officials:
References:
Clinical trial NCT05581550: Somatostatin Receptor Imaging in NPC, EBV Related Cancers
Official title: Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Nasopharyngeal Cancer
Epstein-Barr Virus Related Carcinoma
Keywords: Somatostatin
EBV
NPC
Rare Cancer
Lead sponsor: National Cancer Centre, Singapore
Sponsor class: OTHER
Collaborators: name: National Cancer Centre Research Fund
First posted: 2022-10-14
Enrollment: 50
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.


Eligibility criteria: Inclusion Criteria:

* Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
* Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
* Histologically confirmed NPC
* Above 21 years of age

Exclusion Criteria:

* Patients below 21 years of age
* Pregnant and breast feeding ladies

Primary outcomes:
measure: Amount of tracer uptake in the tumour lesions of NPC patients
timeFrame: From time of tracer injection to time the scan is performed
Secondary outcomes:
measure: Amount of tracer uptake in the tumour lesions of patients with EBV related cancers
timeFrame: From time of tracer injection to time the scan is performed
measure: Number of somatostatin receptors in patient biopsy samples
timeFrame: Upon signing the informed consent form
measure: Amount of somatostatin circulating tumour cells in patient blood samples
timeFrame: At the time of scan
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore
Study officials:
affiliation: National Cancer Centre, Singapore
name: Wen Long Nei, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000350: Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
Official title: Effects of Stimulant Dependence on Human Striatal Dopamine System
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Amphetamine-Related Disorders
Tobacco Use Disorder
Keywords: amphetamine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether DAT availability, assessed by WIN binding, in the striatum is altered in cocaine or methamphetamine dependence. To determine whether DA synthesis capacity, assessed by FDOPA uptake, in the striatum is altered in Coc or Meth dependence. To determine whether the PET tracers, WIN or FDOPA, will differentiate Meth induced alterations from those induced by Coc use. To determine whether the PET characterization of striatal alterations observed at 3-5 days since last drug use persists at least 3 months after last drug use.

Detailed description: 4-5 Day inpatient study. Participant will have scanned pictures (MRI \& PET scans) taken of their brain after being injected with a small amount of WIN, a radioactive substance. Participants give daily urine samples and fill out health related questionnaires. It is important to determine whether the alterations characterized within one week of last drug use persist over a longer time period. Based on results of the studies from aims 1 \& 2, we will decide which of the 2 probes, WIN or FDOPA-PET is the more sensitive index of stimulant-dependency-induced changes.

Eligibility criteria: Inclusion Criteria:

M/F, ages 21-50. Meet DSM-IV criteria for methamphetamine and nicotine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Friends Research Institute
state: California
Study officials:
affiliation: Friends Research Institute, Inc.
name: Walter Ling, M.D.
role: PRINCIPAL_INVESTIGATOR
References: